Horizon Sees Blockbuster Future For Tepezza After US Approval

First Treatment For Thyroid Eye Condition

Once a pariah because of its price gouging, the new approval represents a change of tack from Horizon.

Eye
The FDA is once again well ahead of its scheduled decision date • Source: Shutterstock

Horizon Therapeutics PLC has gained approval for its thyroid eye disease treatment Tepezza (teprotumumab-trbw) from the US Food and Drug Administration, six weeks ahead of schedule.

The Dublin, Ireland-domiciled company has gained notoriety in recent years, thanks to its practice of buying up established drugs and...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip